The activation of the mTOR pathway results in drug resistance in many cancers, inducing breast cancer resisted to trastuzumab, tamoxifen and endocrine therapy, prostate cancer resisted to vincristine, and ovarian cancer resisted to cisplatin (53). Here, MTOR is linked to cancer.